- Company finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related to the company’s support of certain independent charitable co-pay foundations from 2010 to 2014
- As part of these settlements, Novartis has agreed to new corporate integrity obligations in the US through 2025
- Novartis embarks on new approach to meet the educational needs of physicians by setting new standard through digitally enabled education programs …
- Sandoz evaluating next steps, including potential appeal to US Supreme Court
- Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
- Sandoz remains deeply committed to making Erelzi available to US patients as soon as possible, contributing to a more sustainable healthcare system
Holzkirchen, Germany, July 1, 2020 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US …
Sandoz News Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case
- Sandoz evaluating next steps, including potential appeal to US Supreme Court
- Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
- Sandoz remains deeply committed to making Erelzi available to US patients as soon as possible, contributing to a more sustainable healthcare system
Holzkirchen, Germany, July 1, 2020 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US Court of …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia